<code id='8C40FCEBEF'></code><style id='8C40FCEBEF'></style>
    • <acronym id='8C40FCEBEF'></acronym>
      <center id='8C40FCEBEF'><center id='8C40FCEBEF'><tfoot id='8C40FCEBEF'></tfoot></center><abbr id='8C40FCEBEF'><dir id='8C40FCEBEF'><tfoot id='8C40FCEBEF'></tfoot><noframes id='8C40FCEBEF'>

    • <optgroup id='8C40FCEBEF'><strike id='8C40FCEBEF'><sup id='8C40FCEBEF'></sup></strike><code id='8C40FCEBEF'></code></optgroup>
        1. <b id='8C40FCEBEF'><label id='8C40FCEBEF'><select id='8C40FCEBEF'><dt id='8C40FCEBEF'><span id='8C40FCEBEF'></span></dt></select></label></b><u id='8C40FCEBEF'></u>
          <i id='8C40FCEBEF'><strike id='8C40FCEBEF'><tt id='8C40FCEBEF'><pre id='8C40FCEBEF'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:fashion    Page View:9144
          Several amyloid plaques forming between neurons in a brain
          Amyloid plaques forming between neurons. Adobe

          The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

          The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

          advertisement

          Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          Acelyrin, a rare IPO success, stumbles in its first big test
          Acelyrin, a rare IPO success, stumbles in its first big test

          MarkLennihan/APThebiotechcompanyAcelyrin,whichraisedmorethan$500millioninanIPOthisyear,ranintoitsfir

          read more
          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more

          FDA proposes changes to key medical devices approval pathway

          Lastweek,theFDAreleasedatrioofguidelinesclarifyingthewaytheyplantoevaluatedevicesthatgothroughthe510